RVC BioFund helps to create personalized medicine in Russia

RVC BioFund helps to create personalized medicine in Russia RVC BioFund and biopharmaceutical company AstraZeneca signed a memorandum of cooperation, which should result in the creation of infrastructure for the development of personalized medicine, as well as in solving the most pressing problems facing Russian health care. One of the participants of the memorandum is the V.A. Almazov Federal Heart, Blood and Endocrinology Centre.

Russia's first biobank Russian National BioService will be created under this cooperation. It is a unique infrastructure that will enhance the innovative potential of Russia in biomedicine.

Partners' efforts will be concentrated in several therapeutic areas, including cardiology and endocrinology, as the cardiovascular and endocrine diseases are the main causes of mortality in the Russian Federation. The understanding of causes and course of these diseases, as well as increased opportunities for their prevention, diagnosis and treatment is one of the key priorities for the development of health care.

Russian National BioService, which will start working in the second half of 2013, will provide the storage and study of biological samples characteristics to conduct biomedical research. The project also involves the creation of laboratories and formation of a broad network of participating research organizations throughout Russia. Russian National BioService will become the infrastructural platform for the further development of personalized medicine.

Nenad Pavletic, the president of AstraZeneca Russia says that Russia has a great innovation potential that can and should be developed. We strive to create an efficient infrastructure here by combining forces with our partners, V.A. Almazov Center and RVC BioFund, for the conduction of biomedical research, which will contribute to the further development of R&D in Russia and increase the attractiveness of the country for the international medical and biological industry.

Each party will bring its resources to the project: V.A. Almazov Center will bring its scientific expertise and existing infrastructure for biomedical research; RVC BioFund – its expertise in venture capital, AstraZeneca - the provision of expert advice and support for the creation of Biobank that meets all international standards.





https://www.venture-news.ru/ipo-news/64680-mozhno-li-vyigrat-v-kazino-vsya-pravda-kotoraya-shokiruet-kazhdogo.html